Beta Pharmaceuticals: MCLA-129 is currently undergoing indications exploration in the field of lung cancer.

On August 19th, Beida Pharmaceuticals replied to investors' questions on the interactive platform, stating that MCLA-129 is a bispecific antibody targeting EGFR and c-Met dual targets. It is currently being explored for indications in the field of lung cancer. A Phase II study recently initiated focusing on patients with driver gene-positive and MET amplification has enrolled the first patient. If there are any significant research developments, the company will promptly disclose them.